<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35028901</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?</ArticleTitle><Pagination><StartPage>1850</StartPage><EndPage>1861</EndPage><MedlinePgn>1850-1861</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-021-02696-0</ELocationID><Abstract><AbstractText>SARS-CoV-2 infects cells via its spike protein binding to its surface receptor on target cells and results in acute symptoms involving especially the lungs known as COVID-19. However, increasing evidence indicates that many patients develop a chronic condition characterized by fatigue and neuropsychiatric symptoms, termed long-COVID. Most of the vaccines produced so far for COVID-19 direct mammalian cells via either mRNA or an adenovirus vector to express the spike protein, or administer recombinant spike protein, which is recognized by the immune system leading to the production of neutralizing antibodies. Recent publications provide new findings that may help decipher the pathogenesis of long-COVID. One paper reported perivascular inflammation in brains of deceased patients with COVID-19, while others showed that the spike protein could damage the endothelium in an animal model, that it could disrupt an in vitro model of the blood-brain barrier (BBB), and that it can cross the BBB resulting in perivascular inflammation. Moreover, the spike protein appears to share antigenic epitopes with human molecular chaperons resulting in autoimmunity and can activate toll-like receptors (TLRs), leading to release of inflammatory cytokines. Moreover, some antibodies produced against the spike protein may not be neutralizing, but may change its conformation rendering it more likely to bind to its receptor. As a result, one wonders whether the spike protein entering the brain or being expressed by brain cells could activate microglia, alone or together with inflammatory cytokines, since protective antibodies could not cross the BBB, leading to neuro-inflammation and contributing to long-COVID. Hence, there is urgent need to better understand the neurotoxic effects of the spike protein and to consider possible interventions to mitigate spike protein-related detrimental effects to the brain, possibly via use of small natural molecules, especially the flavonoids luteolin and quercetin.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Theoharides</LastName><ForeName>Theoharis C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-1598-460X</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, 136 Harrison Avenue, Suite 304, Boston, MA, 02111, USA. theoharis.theoharides@tufts.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, 02111, USA. theoharis.theoharides@tufts.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Internal Medicine and Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, 02111, USA. theoharis.theoharides@tufts.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuro-Immune Medicine, Nova Southeastern University, Clearwater, FL, 33759, USA. theoharis.theoharides@tufts.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Blood-brain barrier</Keyword><Keyword MajorTopicYN="N">Brain</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Endothelial cells</Keyword><Keyword MajorTopicYN="N">Receptor</Keyword><Keyword MajorTopicYN="N">Spike protein</Keyword></KeywordList><CoiStatement>The author is Scientific Director of Algonot LLC that develops flavonoid-containing dietary supplements.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35028901</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pii">10.1007/s12035-021-02696-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613&#x2013;620. doi: 10.1038/s41423-020-0400-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0400-4</ArticleId><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):1586&#x2013;1592. doi: 10.1126/science.abd4251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4251</ArticleId><ArticleId IdType="pmc">PMC7464562</ArticleId><ArticleId IdType="pubmed">32694201</ArticleId></ArticleIdList></Reference><Reference><Citation>Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146(5):949&#x2013;959. doi: 10.1016/j.jaci.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7522622</ArticleId><ArticleId IdType="pubmed">33007328</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992&#x2013;1000. doi: 10.1016/j.chom.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the &#x2018;cytokine storm&#x2019; in COVID-19. J Inf Secur. 2020;80(6):607&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620&#x2013;2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69(3):379&#x2013;388. doi: 10.33549/physiolres.934492.</Citation><ArticleIdList><ArticleId IdType="doi">10.33549/physiolres.934492</ArticleId><ArticleId IdType="pmc">PMC8648321</ArticleId><ArticleId IdType="pubmed">32469225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D, Salah EH, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28&#x2013;33. doi: 10.1038/s41591-020-01202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128&#x2013;136. doi: 10.1016/j.jaci.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123&#x2013;1130. doi: 10.1080/22221751.2020.1770129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Salvati L, Maggi L, et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020;130(9):4694&#x2013;4703. doi: 10.1172/JCI138554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138554</ArticleId><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104370</ArticleId><ArticleId IdType="pmc">PMC7194648</ArticleId><ArticleId IdType="pubmed">32344321</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J Allergy Clin Immunol. 2020;146(3):518&#x2013;534. doi: 10.1016/j.jaci.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Gallenga CE, et al. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">33016027</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473&#x2013;474. doi: 10.1126/science.abb8925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475&#x2013;484. doi: 10.1038/s41577-021-00578-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00578-z</ArticleId><ArticleId IdType="pmc">PMC8246128</ArticleId><ArticleId IdType="pubmed">34211186</ArticleId></ArticleIdList></Reference><Reference><Citation>Letizia AG, Ge Y, Vangeti S, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9(7):712&#x2013;720. doi: 10.1016/S2213-2600(21)00158-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00158-2</ArticleId><ArticleId IdType="pmc">PMC8049591</ArticleId><ArticleId IdType="pubmed">33865504</ArticleId></ArticleIdList></Reference><Reference><Citation>Puranik A, Lenehan PJ, Silvert E et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021.</Citation></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409&#x2013;424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. (2020) Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J Med Virol.</Citation><ArticleIdList><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V, Sohaei D, Diamandis EP, Prassas I. (2020) COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci 1-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Inf Secur. 2021;82(3):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71&#x2013;76. doi: 10.1038/s41586-020-2247-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2247-3</ArticleId><ArticleId IdType="pmc">PMC7250000</ArticleId><ArticleId IdType="pubmed">32376954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>de Erausquin GA, Snyder H, Carrillo M, Hosseini AA, Brugha TS, Seshadri S. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17(6):1056&#x2013;1065. doi: 10.1002/alz.12255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12255</ArticleId><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="pubmed">33399270</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291&#x2013;2293. doi: 10.1056/NEJMc2031364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268&#x2013;2270. doi: 10.1056/NEJMc2008597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3&#x2013;19. doi: 10.3233/JAD-200581.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200581</ArticleId><ArticleId IdType="pmc">PMC7660990</ArticleId><ArticleId IdType="pubmed">32538857</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar S, Najjar A, Chong DJ, et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020;17(1):231. doi: 10.1186/s12974-020-01896-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01896-0</ArticleId><ArticleId IdType="pmc">PMC7406702</ArticleId><ArticleId IdType="pubmed">32758257</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Bhushan B, Maurya A, Mishra G, Singh SK, Awasthi R. Novel coronavirus disease 2019 (COVID-19) and neurodegenerative disorders. Dermatol Ther. 2020;33(4):e13591. doi: 10.1111/dth.13591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13591</ArticleId><ArticleId IdType="pmc">PMC7261984</ArticleId><ArticleId IdType="pubmed">32412679</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7(11):2221&#x2013;2230. doi: 10.1002/acn3.51210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51210</ArticleId><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann Neurol. 2020;88(1):1&#x2013;11. doi: 10.1002/ana.25807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25807</ArticleId><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Nepal G, Rehrig JH, Shrestha GS, et al. Neurological manifestations of COVID-19: a systematic review. Crit Care. 2020;24(1):421. doi: 10.1186/s13054-020-03121-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03121-z</ArticleId><ArticleId IdType="pmc">PMC7356133</ArticleId><ArticleId IdType="pubmed">32660520</ArticleId></ArticleIdList></Reference><Reference><Citation>Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020;41(12):3437&#x2013;3470. doi: 10.1007/s10072-020-04801-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04801-y</ArticleId><ArticleId IdType="pmc">PMC7577367</ArticleId><ArticleId IdType="pubmed">33089477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazari S, Azari JA, Mirmoeeni S, et al. Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis. Brain Behav. 2021;11:e02025. doi: 10.1002/brb3.2025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2025</ArticleId><ArticleId IdType="pmc">PMC7994971</ArticleId><ArticleId IdType="pubmed">33421351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5-6):402&#x2013;414. doi: 10.1177/1073858420941476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420941476</ArticleId><ArticleId IdType="pubmed">32684080</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin SN, Venkatesh S, Nelson KE, et al. Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. Ann Clin Transl Neurol. 2021;8(4):918&#x2013;928. doi: 10.1002/acn3.51314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51314</ArticleId><ArticleId IdType="pmc">PMC8013889</ArticleId><ArticleId IdType="pubmed">33616290</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24):4017&#x2013;4020. doi: 10.1021/acschemneuro.0c00725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongur D, Perlis R, Goff D. Psychiatry and COVID-19. JAMA. 2020;324(12):1149&#x2013;1150. doi: 10.1001/jama.2020.14294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.14294</ArticleId><ArticleId IdType="pubmed">32960247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531&#x2013;542. doi: 10.1016/j.bbi.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7260522</ArticleId><ArticleId IdType="pubmed">32485289</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med. 2020;383(6):510&#x2013;512. doi: 10.1056/NEJMp2008017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2008017</ArticleId><ArticleId IdType="pubmed">32283003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang YT, Yang Y, Li W, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228&#x2013;229. doi: 10.1016/S2215-0366(20)30046-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30046-8</ArticleId><ArticleId IdType="pmc">PMC7128153</ArticleId><ArticleId IdType="pubmed">32032543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon JA, Borja SE. The COVID-19 pandemic: setting the mental health research agenda. Biol Psychiatry. 2020;88(2):130&#x2013;131. doi: 10.1016/j.biopsych.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7233229</ArticleId><ArticleId IdType="pubmed">32425206</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130&#x2013;140. doi: 10.1016/S2215-0366(20)30462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30462-4</ArticleId><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T, Landi D, Liguori C (2020) COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450256</ArticleId><ArticleId IdType="pubmed">32852580</ArticleId></ArticleIdList></Reference><Reference><Citation>Steardo L, Jr, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry. 2020;10(1):261. doi: 10.1038/s41398-020-00949-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-00949-5</ArticleId><ArticleId IdType="pmc">PMC7391235</ArticleId><ArticleId IdType="pubmed">32732883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shader RI. COVID-19 and depression. Clin Ther. 2020;42(6):962&#x2013;963. doi: 10.1016/j.clinthera.2020.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2020.04.010</ArticleId><ArticleId IdType="pmc">PMC7184005</ArticleId><ArticleId IdType="pubmed">32362345</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CM, Komisar JR, Mourad A, Kincaid BR (2020) COVID-19-associated brief psychotic disorder. BMJ Case Rep 13(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418683</ArticleId><ArticleId IdType="pubmed">32784244</ArticleId></ArticleIdList></Reference><Reference><Citation>Druss BG. Addressing the COVID-19 pandemic in populations with serious mental illness. JAMA Psychiatry. 2020;77(9):891&#x2013;892. doi: 10.1001/jamapsychiatry.2020.0894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2020.0894</ArticleId><ArticleId IdType="pubmed">32242888</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue. Biofactors. 2021;47(2):232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. 2021;8(5):1073&#x2013;1085. doi: 10.1002/acn3.51350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano GB, Buttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: The pathogenesis of long-term neuropsychiatric COVID-19 and the role of microglia, mitochondria, and persistent neuroinflammation: a hypothesis. Med Sci Monit. 2021;27:e933015. doi: 10.12659/MSM.933015.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.933015</ArticleId><ArticleId IdType="pmc">PMC8120907</ArticleId><ArticleId IdType="pubmed">34016942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona CoVHORT. PLoS One. 2021;16(8):e0254347. doi: 10.1371/journal.pone.0254347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon J, Msika EF, Queneau M, Farid K, Paquet C. Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J Neurol. 2021;Jun 18:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8211714</ArticleId><ArticleId IdType="pubmed">34143277</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Yang D, Lewis A, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J Neurol Sci. 2021;426:117486. doi: 10.1016/j.jns.2021.117486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117486</ArticleId><ArticleId IdType="pmc">PMC8113108</ArticleId><ArticleId IdType="pubmed">34000678</ArticleId></ArticleIdList></Reference><Reference><Citation>Podlesek A, Komidar L, Kavcic V. The relationship between perceived stress and subjective cognitive decline during the COVID-19 epidemic. Front Psychol. 2021;12:647971. doi: 10.3389/fpsyg.2021.647971.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.647971</ArticleId><ArticleId IdType="pmc">PMC8374330</ArticleId><ArticleId IdType="pubmed">34421707</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips S, Williams MA. Confronting our next national health disaster - long-haul Covid. N Engl J Med. 2021;385(7):577&#x2013;579. doi: 10.1056/NEJMp2109285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2109285</ArticleId><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Sarkar S, Fram TR et al (2021) Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI. Insight 6(15)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuaid C, Brady M, Deane R. SARS-CoV-2: is there neuroinvasion? Fluids Barriers CNS. 2021;18(1):32. doi: 10.1186/s12987-021-00267-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12987-021-00267-y</ArticleId><ArticleId IdType="pmc">PMC8278192</ArticleId><ArticleId IdType="pubmed">34261487</ArticleId></ArticleIdList></Reference><Reference><Citation>Veleri S (2021) Neurotropism of SARS-CoV-2 and neurological diseases of the central nervous system in COVID-19 patients. Exp Brain Res</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8543422</ArticleId><ArticleId IdType="pubmed">34694467</ArticleId></ArticleIdList></Reference><Reference><Citation>Welcome MO, Mastorakis NE. Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection. Inflammopharmacology. 2021;29(4):939&#x2013;963. doi: 10.1007/s10787-021-00806-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00806-x</ArticleId><ArticleId IdType="pmc">PMC8021940</ArticleId><ArticleId IdType="pubmed">33822324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021;6(1):337. doi: 10.1038/s41392-021-00719-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Zhang C, Israelow B et al (2021) Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Zhong S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089&#x2013;1096. doi: 10.1086/444461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/444461</ArticleId><ArticleId IdType="pmc">PMC7107994</ArticleId><ArticleId IdType="pubmed">16163626</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168&#x2013;175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao L, Yang Y, Yu W, et al. The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys. Signal Transduct Target Ther. 2021;6(1):169. doi: 10.1038/s41392-021-00591-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00591-7</ArticleId><ArticleId IdType="pmc">PMC8065334</ArticleId><ArticleId IdType="pubmed">33895780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagre A, Lewis J, Eckley M, et al. SARS-CoV-2 infection, neuropathogenesis and transmission among deer mice: implications for spillback to New World rodents. PLoS Pathog. 2021;17(5):e1009585. doi: 10.1371/journal.ppat.1009585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009585</ArticleId><ArticleId IdType="pmc">PMC8168874</ArticleId><ArticleId IdType="pubmed">34010360</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann DH, Tsukahara T, Weinreb C et al (2020) Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 6(31)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing brain capillaries in coronavirus disease 2019. JAMA Neurol. 2021;78(6):760&#x2013;762. doi: 10.1001/jamaneurol.2021.0225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.0225</ArticleId><ArticleId IdType="pmc">PMC7881367</ArticleId><ArticleId IdType="pubmed">33576767</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivgoulis G, Palaiodimou L, Zand R, et al. COVID-19 and cerebrovascular diseases: a comprehensive overview. Ther Adv Neurol Disord. 2020;13:1756286420978004. doi: 10.1177/1756286420978004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420978004</ArticleId><ArticleId IdType="pmc">PMC7727052</ArticleId><ArticleId IdType="pubmed">33343709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass DI, Meyer RM, Barros G, et al. The impact of the COVID-19 pandemic on cerebrovascular disease. Semin Vasc Surg. 2021;34(2):20&#x2013;27. doi: 10.1053/j.semvascsurg.2021.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semvascsurg.2021.05.001</ArticleId><ArticleId IdType="pmc">PMC8136291</ArticleId><ArticleId IdType="pubmed">34144743</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhamoon MS, Thaler A, Gururangan K, et al. Acute cerebrovascular events with COVID-19 infection. Stroke. 2021;52(1):48&#x2013;56. doi: 10.1161/STROKEAHA.120.031668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.031668</ArticleId><ArticleId IdType="pubmed">33280551</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes I, Karmirian K, Oliveira JT, et al. SARS-CoV-2 infection of the central nervous system in a 14-month-old child: a case report of a complete autopsy. Lancet Reg Health Am. 2021;2:100046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397543</ArticleId><ArticleId IdType="pubmed">34485969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595(7868):565&#x2013;571. doi: 10.1038/s41586-021-03710-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani A, Muller L, Ostermann PN, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230. doi: 10.15252/embj.2020106230.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106230</ArticleId><ArticleId IdType="pmc">PMC7560208</ArticleId><ArticleId IdType="pubmed">32876341</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995&#x2013;998. doi: 10.1021/acschemneuro.0c00122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00122</ArticleId><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitt AG, Manimala S, White T, et al. SARS-CoV-2 exacerbates COVID-19 pathology through activation of the complement and kinin systems. Front Immunol. 2021;12:767347. doi: 10.3389/fimmu.2021.767347.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.767347</ArticleId><ArticleId IdType="pmc">PMC8602850</ArticleId><ArticleId IdType="pubmed">34804054</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnik M, Beeraka NM, Uthaiah CA, et al. A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development. Mol Neurobiol. 2021;5:1&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8179092</ArticleId><ArticleId IdType="pubmed">34089508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberman AC, Trias E, da Silva CL, et al. Neuroimmune and inflammatory signals in complex disorders of the central nervous system. Neuroimmunomodulation. 2018;25(5-6):246&#x2013;270. doi: 10.1159/000494761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000494761</ArticleId><ArticleId IdType="pubmed">30517945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384(5):481&#x2013;483. doi: 10.1056/NEJMc2033369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2033369</ArticleId><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro CM, Mulvey J, Kubiak J, et al. Severe COVID-19: a multifaceted viral vasculopathy syndrome. Ann Diagn Pathol. 2021;50:151645. doi: 10.1016/j.anndiagpath.2020.151645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anndiagpath.2020.151645</ArticleId><ArticleId IdType="pmc">PMC7553104</ArticleId><ArticleId IdType="pubmed">33248385</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar B, Patel K, Ho W, Luo JJ, Hu W. Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19. J Med Virol. 2021;93(4):1983&#x2013;1998. doi: 10.1002/jmv.26720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26720</ArticleId><ArticleId IdType="pmc">PMC7897247</ArticleId><ArticleId IdType="pubmed">33300152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng JH, Sun A, Je HS, Tan EK. (2021) Unravelling pathophysiology of neurological and psychiatric complications of COVID-19 using brain organoids. Neuroscientist 10738584211015136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9902967</ArticleId><ArticleId IdType="pubmed">34036855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Madore C, Bordeleau M, Tian L, Verkhratsky A. Neuropathobiology of COVID-19: the role for glia. Front Cell Neurosci. 2020;14:592214. doi: 10.3389/fncel.2020.592214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.592214</ArticleId><ArticleId IdType="pmc">PMC7693550</ArticleId><ArticleId IdType="pubmed">33304243</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon CL, Staples H, Gazi M, Carrion R, Hsieh J. SARS-CoV-2 targets glial cells in human cortical organoids. Stem Cell Rep. 2021;16(5):1156&#x2013;1164. doi: 10.1016/j.stemcr.2021.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.01.016</ArticleId><ArticleId IdType="pmc">PMC8111796</ArticleId><ArticleId IdType="pubmed">33979600</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Mast cells: the immune gate to the brain. Life Sci. 1990;46:607&#x2013;617. doi: 10.1016/0024-3205(90)90129-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(90)90129-F</ArticleId><ArticleId IdType="pubmed">2407920</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Harthi L, Campbell E, Schneider JA, Bennett DA. What HIV in the brain can teach us about SARS-CoV-2 neurological complications? AIDS Res Hum Retrovir. 2021;37(4):255&#x2013;265. doi: 10.1089/aid.2020.0161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/aid.2020.0161</ArticleId><ArticleId IdType="pmc">PMC8035916</ArticleId><ArticleId IdType="pubmed">32683890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Soh WT, Kishikawa JI, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021;9(7):712&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142859</ArticleId><ArticleId IdType="pubmed">34139176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahi N, Chahinian H, Fantini J. (2021) Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination? J Infect.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351274</ArticleId><ArticleId IdType="pubmed">34384810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015&#x2013;e02019. doi: 10.1128/JVI.02015-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02015-19</ArticleId><ArticleId IdType="pmc">PMC7022351</ArticleId><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy WJ, Longo DL. (2021) A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med.</Citation><ArticleIdList><ArticleId IdType="pubmed">34818473</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C et al. (2021) Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM et al. (2021) Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley CM, Johns C, Ngo TT et al. (2021) Anti-SARS-CoV-2 and autoantibody profiles in the cerebrospinal fluid of 3 teenaged patients with COVID-19 and subacute neuropsychiatric symptoms. JAMA Neurol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546622</ArticleId><ArticleId IdType="pubmed">34694339</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosavi F, Hosseini R, Saso L, Firuzi O. Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Devel Ther. 2016;10:23&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694682</ArticleId><ArticleId IdType="pubmed">26730179</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents. 2020;34(5):1633&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Potential association of mast cells with COVID-19. Ann Allergy Asthma Immunol. 2020;126(3):217&#x2013;218. doi: 10.1016/j.anai.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7644430</ArticleId><ArticleId IdType="pubmed">33161155</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther. 2020;42(10):1850&#x2013;1852. doi: 10.1016/j.clinthera.2020.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2020.08.006</ArticleId><ArticleId IdType="pmc">PMC7430296</ArticleId><ArticleId IdType="pubmed">32883529</ArticleId></ArticleIdList></Reference><Reference><Citation>Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. Biofactors. 2020;46(6):927&#x2013;933. doi: 10.1002/biof.1696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1696</ArticleId><ArticleId IdType="pubmed">33296106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128(9):1323&#x2013;1326. doi: 10.1161/CIRCRESAHA.121.318902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.318902</ArticleId><ArticleId IdType="pmc">PMC8091897</ArticleId><ArticleId IdType="pubmed">33784827</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan S, Kenchappa DB, Leo MD. SARS-CoV-2 spike protein induces degradation of junctional proteins that maintain endothelial barrier integrity. Front Cardiovasc Med. 2021;8:687783. doi: 10.3389/fcvm.2021.687783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.687783</ArticleId><ArticleId IdType="pmc">PMC8225996</ArticleId><ArticleId IdType="pubmed">34179146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Jeon MT, Kim KS, Lee S, Kim S, Kim DG. Spike proteins of SARS-CoV-2 induce pathological changes in molecular delivery and metabolic function in the brain endothelial cells. Viruses. 2021;13(10):2021. doi: 10.3390/v13102021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13102021</ArticleId><ArticleId IdType="pmc">PMC8538996</ArticleId><ArticleId IdType="pubmed">34696455</ArticleId></ArticleIdList></Reference><Reference><Citation>DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. (2021) SARS-CoV-2 spike protein disrupts blood-brain barrier integrity via rhoa activation. J Neuroimmune Pharmacol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536479</ArticleId><ArticleId IdType="pubmed">34687399</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Patra T, Vijayamahantesh RR. SARS-CoV-2 spike protein induces paracrine senescence and leukocyte adhesion in endothelial cells. J Virol. 2021;95(17):e0079421. doi: 10.1128/JVI.00794-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00794-21</ArticleId><ArticleId IdType="pmc">PMC8354225</ArticleId><ArticleId IdType="pubmed">34160250</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis. 2020;146:105131. doi: 10.1016/j.nbd.2020.105131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105131</ArticleId><ArticleId IdType="pmc">PMC7547916</ArticleId><ArticleId IdType="pubmed">33053430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea EM, Logsdon AF, Hansen KM, et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci. 2021;24(3):368&#x2013;378. doi: 10.1038/s41593-020-00771-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaddaj-Mallat R, Aldib N, Bernard M, et al. SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein. Neurobiol Dis. 2021;161:105561. doi: 10.1016/j.nbd.2021.105561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105561</ArticleId><ArticleId IdType="pmc">PMC8590447</ArticleId><ArticleId IdType="pubmed">34780863</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino L, Vitale AM, Caruso BC, et al. The role of molecular chaperones in virus infection and implications for understanding and treating COVID-19. J Clin Med. 2020;9(11):3518. doi: 10.3390/jcm9113518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113518</ArticleId><ArticleId IdType="pmc">PMC7693988</ArticleId><ArticleId IdType="pubmed">33143379</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Bandyopadhyay M. Molecular docking of SARS-COV-2 spike epitope sequences identifies heterodimeric peptide-protein complex formation with human Zo-1, TLR8 and brain specific glial proteins. Med Hypotheses. 2021;157:110706. doi: 10.1016/j.mehy.2021.110706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110706</ArticleId><ArticleId IdType="pmc">PMC8511551</ArticleId><ArticleId IdType="pubmed">34673372</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlie-Silva I, Araujo APC, Guimaraes ATB, et al. Toxicological insights of spike fragments SARS-CoV-2 by exposure environment: a threat to aquatic health? J Hazard Mater. 2021;419:126463. doi: 10.1016/j.jhazmat.2021.126463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhazmat.2021.126463</ArticleId><ArticleId IdType="pmc">PMC8226002</ArticleId><ArticleId IdType="pubmed">34216962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Dong H, Li N, et al. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis. J Neuroinflammation. 2016;13(1):127. doi: 10.1186/s12974-016-0592-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0592-9</ArticleId><ArticleId IdType="pmc">PMC4888609</ArticleId><ArticleId IdType="pubmed">27245661</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura DS, Sultan S, Georgin-Lavialle S, et al. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression. PLoS One. 2012;7(6):e39468. doi: 10.1371/journal.pone.0039468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039468</ArticleId><ArticleId IdType="pmc">PMC3379977</ArticleId><ArticleId IdType="pubmed">22745762</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin LB, Pohlau D, Raithel M, et al. Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases. Brain Behav Immun. 2015;50:314&#x2013;321. doi: 10.1016/j.bbi.2015.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.07.002</ArticleId><ArticleId IdType="pubmed">26162709</ArticleId></ArticleIdList></Reference><Reference><Citation>Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099&#x2013;1104. doi: 10.1016/j.jaci.2010.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2010.08.035</ArticleId><ArticleId IdType="pmc">PMC3753019</ArticleId><ArticleId IdType="pubmed">21035176</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639&#x2013;656. doi: 10.1080/1744666X.2019.1596800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1596800</ArticleId><ArticleId IdType="pmc">PMC7003574</ArticleId><ArticleId IdType="pubmed">30884251</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163&#x2013;172. doi: 10.1056/NEJMra1409760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1409760</ArticleId><ArticleId IdType="pubmed">26154789</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241. doi: 10.3390/ijms20174241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20174241</ArticleId><ArticleId IdType="pmc">PMC6747121</ArticleId><ArticleId IdType="pubmed">31480219</ArticleId></ArticleIdList></Reference><Reference><Citation>Motta Junior JDS, Miggiolaro AFRD, Nagashima S, et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol. 2020;11:574862. doi: 10.3389/fimmu.2020.574862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.574862</ArticleId><ArticleId IdType="pmc">PMC7530169</ArticleId><ArticleId IdType="pubmed">33042157</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. Front Biosci. 2007;12:1615&#x2013;1628. doi: 10.2741/2174.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2174</ArticleId><ArticleId IdType="pubmed">17127408</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozniecki JJ, Dimitriadou V, Lambracht-Hall M, Pang X, Theoharides TC. Morphological and functional demonstration of rat dura mast cell-neuron interactions in vitro and in vivo. Brain Res. 1999;849:1&#x2013;15. doi: 10.1016/S0006-8993(99)01855-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(99)01855-7</ArticleId><ArticleId IdType="pubmed">10592282</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitriadou V, Rouleau A, Trung Tuong MD, et al. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience. 1997;77:829&#x2013;839. doi: 10.1016/S0306-4522(96)00488-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(96)00488-5</ArticleId><ArticleId IdType="pubmed">9070755</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriksen E, van BD, Oosting RS, Redegeld FA. Mast cells in neuroinflammation and brain disorders. Neurosci Biobehav Rev. 2017;79:119&#x2013;133. doi: 10.1016/j.neubiorev.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2017.05.001</ArticleId><ArticleId IdType="pubmed">28499503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang Y, Dong H, Xu Y, Zhang S. Induction of microglial activation by mediators released from mast cells. Cell Physiol Biochem. 2016;38(4):1520&#x2013;1531. doi: 10.1159/000443093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000443093</ArticleId><ArticleId IdType="pubmed">27050634</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD, Facci L, Zusso M, Giusti P. Neuroinflammation, mast cells, and glia: dangerous liaisons. Neuroscientist. 2017;23(5):478&#x2013;498. doi: 10.1177/1073858416687249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858416687249</ArticleId><ArticleId IdType="pubmed">29283023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue J, Jin W, Yang H, et al. Heparan Sulfate facilitates spike protein-mediated SARS-CoV-2 host cell invasion and contributes to increased infection of SARS-CoV-2 G614 mutant and in lung cancer. Front Mol Biosci. 2021;8:649575. doi: 10.3389/fmolb.2021.649575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.649575</ArticleId><ArticleId IdType="pmc">PMC8231436</ArticleId><ArticleId IdType="pubmed">34179075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanzadeh K, Perez PH, Dragotto J, et al. Considerations around the SARS-CoV-2 spike protein with particular attention to COVID-19 brain infection and neurological symptoms. ACS Chem Neurosci. 2020;11(15):2361&#x2013;2369. doi: 10.1021/acschemneuro.0c00373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00373</ArticleId><ArticleId IdType="pubmed">32627524</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Chopra P, Li X, et al. Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2. ACS Cent Sci. 2021;7(6):1009&#x2013;1018. doi: 10.1021/acscentsci.1c00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00010</ArticleId><ArticleId IdType="pmc">PMC8227597</ArticleId><ArticleId IdType="pubmed">34235261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudowska-Sawczuk M, Mroczko B. The role of neuropilin-1 (NRP-1) in SARS-CoV-2 infection: review. J Clin Med. 2021;10(13):2772. doi: 10.3390/jcm10132772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10132772</ArticleId><ArticleId IdType="pmc">PMC8267897</ArticleId><ArticleId IdType="pubmed">34202613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarabipour S, Mac GF (2021) Targeting neuropilins as a viable SARS-CoV-2 treatment. FEBS J</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420456</ArticleId><ArticleId IdType="pubmed">34185437</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Karki CB, Du D, et al. Spike proteins of SARS-CoV and SARS-CoV-2 utilize different mechanisms to bind with human ACE2. Front Mol Biosci. 2020;7:591873. doi: 10.3389/fmolb.2020.591873.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.591873</ArticleId><ArticleId IdType="pmc">PMC7755986</ArticleId><ArticleId IdType="pubmed">33363207</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727&#x2013;11734. doi: 10.1073/pnas.2003138117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Onofrio L, Caraglia M, Facchini G, Margherita V, Placido S, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA. 2020;6(8):FSO605. doi: 10.2144/fsoa-2020-0091.</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/fsoa-2020-0091</ArticleId><ArticleId IdType="pmc">PMC7434222</ArticleId><ArticleId IdType="pubmed">32974046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A, Perlman S. SARS-CoV-2 takes its toll. Nat Immunol. 2021;22(7):801&#x2013;802. doi: 10.1038/s41590-021-00962-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00962-w</ArticleId><ArticleId IdType="pmc">PMC8238877</ArticleId><ArticleId IdType="pubmed">34103714</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh H, Singh A, Khan AA, Gupta V. Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease. Microb Pathog. 2021;158:105023. doi: 10.1016/j.micpath.2021.105023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.105023</ArticleId><ArticleId IdType="pmc">PMC8177310</ArticleId><ArticleId IdType="pubmed">34090983</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat Inflamm. 2021;2021:8874339. doi: 10.1155/2021/8874339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi YS, Yun M. Editorial of Special Issue &#x201c;Regulatory roles of inflammasomes in human diseases&#x201d;. Int J Mol Sci. 2021;22(6):3008. doi: 10.3390/ijms22063008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063008</ArticleId><ArticleId IdType="pmc">PMC7999501</ArticleId><ArticleId IdType="pubmed">33809447</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiese K. The mechanistic target of rapamycin (mTOR): novel considerations as an antiviral treatment. Curr Neurovasc Res. 2020;17(3):332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541431</ArticleId><ArticleId IdType="pubmed">32334502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. J Med Virol. 2020;92(9):1495&#x2013;1500. doi: 10.1002/jmv.26009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26009</ArticleId><ArticleId IdType="pmc">PMC7272823</ArticleId><ArticleId IdType="pubmed">32410266</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryskalin L, Limanaqi F, Frati A, Busceti CL, Fornai F (2018) mTOR-related brain dysfunctions in neuropsychiatric disorders. Int J Mol Sci 19(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121884</ArticleId><ArticleId IdType="pubmed">30061532</ArticleId></ArticleIdList></Reference><Reference><Citation>Espindola OM, Gomes YCP, Brandao CO, et al. Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol. 2021;89(5):1041&#x2013;1045. doi: 10.1002/ana.26041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26041</ArticleId><ArticleId IdType="pmc">PMC8014707</ArticleId><ArticleId IdType="pubmed">33547819</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka Y, Ueda A, Nakagawa T, et al. SARS-CoV-2-related progressive brain white matter lesion associated with an increased cerebrospinal fluid level of IL-6. Intern Med. 2021;60(19):3167&#x2013;3170. doi: 10.2169/internalmedicine.8123-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.8123-21</ArticleId><ArticleId IdType="pmc">PMC8545645</ArticleId><ArticleId IdType="pubmed">34373382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow NA, Anwar F, Covarrubias AE, et al. IL-6 inhibition reduces neuronal injury in a murine model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2021;65(4):403&#x2013;412. doi: 10.1165/rcmb.2021-0072OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0072OC</ArticleId><ArticleId IdType="pmc">PMC8525200</ArticleId><ArticleId IdType="pubmed">34014798</ArticleId></ArticleIdList></Reference><Reference><Citation>Saridaki M, Metallidis S, Grigoropoulou S, et al. Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19) Eur J Clin Microbiol Infect Dis. 2021;40(7):1405&#x2013;1412. doi: 10.1007/s10096-020-04145-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-04145-7</ArticleId><ArticleId IdType="pmc">PMC7846268</ArticleId><ArticleId IdType="pubmed">33515095</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauti R, Shahoha M, Leichtmann-Bardoogo Y, et al. Effect of SARS-CoV-2 proteins on vascular permeability. Elife. 2021;10:e69314. doi: 10.7554/eLife.69314.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.69314</ArticleId><ArticleId IdType="pmc">PMC8545399</ArticleId><ArticleId IdType="pubmed">34694226</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma P, Lybrand ZR, Antopia MC, Hsieh J. Novel targets of SARS-CoV-2 spike protein in human fetal brain development suggest early pregnancy vulnerability. Front Neurosci. 2020;14:614680. doi: 10.3389/fnins.2020.614680.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.614680</ArticleId><ArticleId IdType="pmc">PMC7859280</ArticleId><ArticleId IdType="pubmed">33551727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivanti AJ, Vauloup-Fellous C, Prevot S, et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun. 2020;11(1):3572. doi: 10.1038/s41467-020-17436-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17436-6</ArticleId><ArticleId IdType="pmc">PMC7360599</ArticleId><ArticleId IdType="pubmed">32665677</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Ways to address perinatal mast cell activation and focal brain inflammation, including response to SARS-CoV-2, in autism spectrum disorder. J Pers Med. 2021;11(9):860. doi: 10.3390/jpm11090860.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11090860</ArticleId><ArticleId IdType="pmc">PMC8465360</ArticleId><ArticleId IdType="pubmed">34575637</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Front Cell Neurosci. 2019;13:353. doi: 10.3389/fncel.2019.00353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00353</ArticleId><ArticleId IdType="pmc">PMC6687840</ArticleId><ArticleId IdType="pubmed">31427928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical cross-talk between COVID-19 and Alzheimer&#x2019;s disease. Mol Neurobiol. 2021;58(3):1017&#x2013;1023. doi: 10.1007/s12035-020-02177-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02177-w</ArticleId><ArticleId IdType="pmc">PMC7571527</ArticleId><ArticleId IdType="pubmed">33078369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Ahmed ME, Selvakumar GP, et al. Brain injury-mediated neuroinflammatory response and Alzheimer&#x2019;s disease. Neuroscientist. 2019;26(2):134&#x2013;155. doi: 10.1177/1073858419848293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858419848293</ArticleId><ArticleId IdType="pmc">PMC7274851</ArticleId><ArticleId IdType="pubmed">31092147</ArticleId></ArticleIdList></Reference><Reference><Citation>(2021) WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access. Saudi Med J 42(8):923</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9195550</ArticleId><ArticleId IdType="pubmed">34344822</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752&#x2013;1760. doi: 10.1038/s41591-021-01499-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01499-z</ArticleId><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagris D, Florentin M, Tasoudis P, et al. Immunomodulation and reduction of thromboembolic risk in hospitalized COVID-19 patients: systematic review and meta-analysis of randomized trials. J Clin Med. 2021;10(22):5366. doi: 10.3390/jcm10225366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225366</ArticleId><ArticleId IdType="pmc">PMC8617689</ArticleId><ArticleId IdType="pubmed">34830648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503&#x2013;1516. doi: 10.1056/NEJMoa2028700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128:344&#x2013;350. doi: 10.1159/000063858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000063858</ArticleId><ArticleId IdType="pubmed">12218373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115(2):216&#x2013;223. doi: 10.1016/j.clim.2005.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2005.01.011</ArticleId><ArticleId IdType="pubmed">15885646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayado A, Teodosio C, Garcia-Montero AC, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2015;30(1):124&#x2013;130. doi: 10.1038/leu.2015.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2015.176</ArticleId><ArticleId IdType="pubmed">26153655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol. 2003;171(9):4830&#x2013;4836. doi: 10.4049/jimmunol.171.9.4830.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.9.4830</ArticleId><ArticleId IdType="pubmed">14568962</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. Cardiovasc Res. 2003;59(1):241&#x2013;249. doi: 10.1016/S0008-6363(03)00340-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-6363(03)00340-7</ArticleId><ArticleId IdType="pubmed">12829195</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobio A, Alfonso A, Botana LM. C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCdelta translocation in HMC-1(560) and HMC-1(560,816) cell lines. Immunopharmacol Immunotoxicol. 2015;37(4):380&#x2013;387. doi: 10.3109/08923973.2015.1064132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08923973.2015.1064132</ArticleId><ArticleId IdType="pubmed">26181649</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Jung MY, Olivera A, et al. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016;137(6):1863&#x2013;1871. doi: 10.1016/j.jaci.2015.09.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.09.059</ArticleId><ArticleId IdType="pmc">PMC4899186</ArticleId><ArticleId IdType="pubmed">26774658</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter AE, Sandeep BV, Rao BG, Kalpana VL. Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID-19. Front Pharmacol. 2020;11:583777. doi: 10.3389/fphar.2020.583777.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.583777</ArticleId><ArticleId IdType="pmc">PMC7941276</ArticleId><ArticleId IdType="pubmed">33708109</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouadi B, Ezaouine A, El MM, Blaghen M, Bennis F, Chegdani F. Prediction of anti-COVID 19 therapeutic power of medicinal moroccan plants using molecular docking. Bioinform Biol Insights. 2021;15:11779322211009199. doi: 10.1177/11779322211009199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11779322211009199</ArticleId><ArticleId IdType="pmc">PMC8040561</ArticleId><ArticleId IdType="pubmed">33888980</ArticleId></ArticleIdList></Reference><Reference><Citation>Alesci A, Aragona M, Cicero N, Lauriano ER. (2021) Can nutraceuticals assist treatment and improve covid-19 symptoms? Nat Prod Res 1-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33949266</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Zhu GH, Wang HN, et al. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening. Fitoterapia. 2021;152:104909. doi: 10.1016/j.fitote.2021.104909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2021.104909</ArticleId><ArticleId IdType="pmc">PMC8061081</ArticleId><ArticleId IdType="pubmed">33894315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JS, Chen YH, Huang PH, et al. Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathways. Cardiovasc Diabetol. 2012;11:49. doi: 10.1186/1475-2840-11-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-11-49</ArticleId><ArticleId IdType="pmc">PMC3434011</ArticleId><ArticleId IdType="pubmed">22553973</ArticleId></ArticleIdList></Reference><Reference><Citation>Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472&#x2013;480. doi: 10.1016/j.jpsychires.2006.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2006.05.004</ArticleId><ArticleId IdType="pubmed">16808927</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065&#x2013;2077. doi: 10.2147/CIA.S72728.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S72728</ArticleId><ArticleId IdType="pmc">PMC4259871</ArticleId><ArticleId IdType="pubmed">25506211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim MA, Ramadan HH, Mohammed RN. Evidence that Ginkgo biloba could use in the influenza and coronavirus COVID-19 infections. J Basic Clin Physiol Pharmacol. 2021;32(3):131&#x2013;143. doi: 10.1515/jbcpp-2020-0310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jbcpp-2020-0310</ArticleId><ArticleId IdType="pubmed">33594843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Avalos G, Vargas-Ruiz AP, Gado-Pease NE, et al. Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 M(PRO) Sci Rep. 2021;11(1):15452. doi: 10.1038/s41598-021-94951-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94951-6</ArticleId><ArticleId IdType="pmc">PMC8322093</ArticleId><ArticleId IdType="pubmed">34326429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YQ, Li QS, Zheng XQ, Lu JL, Liang YR. Antiviral effects of green tea EGCG and its potential application against COVID-19. Molecules. 2021;26(13):3962. doi: 10.3390/molecules26133962.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26133962</ArticleId><ArticleId IdType="pmc">PMC8271719</ArticleId><ArticleId IdType="pubmed">34209485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhatre S, Gurav N, Shah M, Patravale V. Entry-inhibitory role of catechins against SARS-CoV-2 and its UK variant. Comput Biol Med. 2021;135:104560. doi: 10.1016/j.compbiomed.2021.104560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2021.104560</ArticleId><ArticleId IdType="pmc">PMC8189743</ArticleId><ArticleId IdType="pubmed">34147855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparello J, D'Aversa E, Papi C, et al. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. Phytomedicine. 2021;87:153583. doi: 10.1016/j.phymed.2021.153583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153583</ArticleId><ArticleId IdType="pmc">PMC8095027</ArticleId><ArticleId IdType="pubmed">34033999</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton E, Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">11121513</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020;46(3):306&#x2013;308. doi: 10.1002/biof.1633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1633</ArticleId><ArticleId IdType="pmc">PMC7267424</ArticleId><ArticleId IdType="pubmed">32339387</ArticleId></ArticleIdList></Reference><Reference><Citation>Richman S, Morris MC, Broderick G, Craddock TJA, Klimas NG, Fletcher MA. Pharmaceutical interventions in chronic fatigue syndrome: a literature-based commentary. Clin Ther. 2019;41(5):798&#x2013;805. doi: 10.1016/j.clinthera.2019.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2019.02.011</ArticleId><ArticleId IdType="pmc">PMC6543846</ArticleId><ArticleId IdType="pubmed">30871727</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris T, Perez-Valero A, Martinez I, et al. Repositioning microbial biotechnology against COVID-19: the case of microbial production of flavonoids. Microb Biotechnol. 2021;14(1):94&#x2013;110. doi: 10.1111/1751-7915.13675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.13675</ArticleId><ArticleId IdType="pmc">PMC7675739</ArticleId><ArticleId IdType="pubmed">33047877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gour A, Manhas D, Bag S, Gorain B, Nandi U. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. Phytother Res. 2021;35(8):4258&#x2013;4283. doi: 10.1002/ptr.7092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7092</ArticleId><ArticleId IdType="pmc">PMC8250405</ArticleId><ArticleId IdType="pubmed">33786876</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzaabi MM, Hamdy R, Ashmawy NS et al. (2021) Flavonoids are promising safe therapy against COVID-19. Phytochem Rev 1-22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139868</ArticleId><ArticleId IdType="pubmed">34054380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar B, Zaidi S, Haque S et al. (2020) In silico studies reveal antiviral effects of traditional Indian spices on COVID-19. Curr Pharm Des</Citation><ArticleIdList><ArticleId IdType="pubmed">33357192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AM, Kunugi H. Propolis, bee honey, and their components protect against coronavirus disease 2019 (COVID-19): a review of in silico, in vitro, and clinical studies. Molecules. 2021;26(5):1232. doi: 10.3390/molecules26051232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26051232</ArticleId><ArticleId IdType="pmc">PMC7956496</ArticleId><ArticleId IdType="pubmed">33669054</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalin A, Lin D, Senthamarai KB et al. (2021) An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor. J Biomol Struct Dyn 1-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">33685364</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Su W, Jin J, et al. Identification of luteolin as enterovirus 71 and coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening. Viruses. 2014;6(7):2778&#x2013;2795. doi: 10.3390/v6072778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6072778</ArticleId><ArticleId IdType="pmc">PMC4113793</ArticleId><ArticleId IdType="pubmed">25036464</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, Qian S, Qian P, Li X. Antiviral activity of luteolin against Japanese encephalitis virus. Virus Res. 2016;220:112&#x2013;116. doi: 10.1016/j.virusres.2016.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2016.04.021</ArticleId><ArticleId IdType="pubmed">27126774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Ma L, Wang H, et al. Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. J Nat Med. 2019;73(3):487&#x2013;496. doi: 10.1007/s11418-019-01287-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11418-019-01287-7</ArticleId><ArticleId IdType="pubmed">30758716</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL. Roles of flavonoids against coronavirus infection. Chem Biol Interact. 2020;328:109211. doi: 10.1016/j.cbi.2020.109211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2020.109211</ArticleId><ArticleId IdType="pmc">PMC7385538</ArticleId><ArticleId IdType="pubmed">32735799</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa G, Maffioli P, D'Angelo A, Di PF. A role for quercetin in coronavirus disease 2019 (COVID-19) Phytother Res. 2020;35(3):1230&#x2013;1236. doi: 10.1002/ptr.6887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6887</ArticleId><ArticleId IdType="pmc">PMC7675685</ArticleId><ArticleId IdType="pubmed">33034398</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35(1):145&#x2013;151. doi: 10.1080/14756366.2019.1690480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14756366.2019.1690480</ArticleId><ArticleId IdType="pmc">PMC6882434</ArticleId><ArticleId IdType="pubmed">31724441</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue G, Gong L, Yuan C, et al. A structural mechanism of flavonoids in inhibiting serine proteases. Food Funct. 2017;8(7):2437&#x2013;2443. doi: 10.1039/C6FO01825D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6FO01825D</ArticleId><ArticleId IdType="pubmed">28644504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K, Ehrhart J, Bai Y, et al. Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflammation. 2008;5:41. doi: 10.1186/1742-2094-5-41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-5-41</ArticleId><ArticleId IdType="pmc">PMC2569027</ArticleId><ArticleId IdType="pubmed">18817573</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A. 2008;105(21):7534&#x2013;7539. doi: 10.1073/pnas.0802865105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802865105</ArticleId><ArticleId IdType="pmc">PMC2396685</ArticleId><ArticleId IdType="pubmed">18490655</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton MD, Rytych JL, Amin R, Johnson RW. Dietary luteolin reduces proinflammatory microglia in the brain of senescent mice. Rejuvenation Res. 2016;19(4):286&#x2013;292. doi: 10.1089/rej.2015.1708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2015.1708</ArticleId><ArticleId IdType="pmc">PMC4971424</ArticleId><ArticleId IdType="pubmed">26918466</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci U S A. 2016;113:E7049&#x2013;E7058. doi: 10.1073/pnas.1604992113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1604992113</ArticleId><ArticleId IdType="pmc">PMC5111711</ArticleId><ArticleId IdType="pubmed">27663735</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol. 2015;135(4):1044&#x2013;1052. doi: 10.1016/j.jaci.2014.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.10.032</ArticleId><ArticleId IdType="pmc">PMC4388775</ArticleId><ArticleId IdType="pubmed">25498791</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AB, Theoharides TC. Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells. J Pharmacol Exp Ther. 2017;361(3):462&#x2013;471. doi: 10.1124/jpet.117.240564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.117.240564</ArticleId><ArticleId IdType="pubmed">28404689</ArticleId></ArticleIdList></Reference><Reference><Citation>Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. Proc Natl Acad Sci U S A. 2018;115(40):E9381&#x2013;E9390. doi: 10.1073/pnas.1810133115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810133115</ArticleId><ArticleId IdType="pmc">PMC6176605</ArticleId><ArticleId IdType="pubmed">30232261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MN, Lee Y, Wu D, Pae M. Luteolin inhibits NLRP3 inflammasome activation via blocking ASC oligomerization. J Nutr Biochem. 2021;92:108614. doi: 10.1016/j.jnutbio.2021.108614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2021.108614</ArticleId><ArticleId IdType="pubmed">33705947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashaari Z, Hadjzadeh MA, Hassanzadeh G, et al. The flavone luteolin improves central nervous system disorders by different mechanisms: a review. J Mol Neurosci. 2018;65(4):491&#x2013;506. doi: 10.1007/s12031-018-1094-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1094-2</ArticleId><ArticleId IdType="pubmed">30083786</ArticleId></ArticleIdList></Reference><Reference><Citation>Calis Z, Mogulkoc R, Baltaci AK. The roles of flavonols/flavonoids in neurodegeneration and neuroinflammation. Mini-Rev Med Chem. 2020;20(15):1475&#x2013;1488. doi: 10.2174/1389557519666190617150051.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557519666190617150051</ArticleId><ArticleId IdType="pubmed">31288717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D, Thangavel R, Kempuraj DD, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Biofactors. 2020;47(2):190&#x2013;197. doi: 10.1002/biof.1687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1687</ArticleId><ArticleId IdType="pubmed">33098588</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Conti P, Economu M. Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin. J Clin Psychopharmacol. 2014;34(2):187&#x2013;189. doi: 10.1097/JCP.0000000000000084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0000000000000084</ArticleId><ArticleId IdType="pubmed">24525647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dajas F, Rivera-Megret F, Blasina F, et al. Neuroprotection by flavonoids. Braz J Med Biol Res. 2003;36(12):1613&#x2013;1620. doi: 10.1590/S0100-879X2003001200002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0100-879X2003001200002</ArticleId><ArticleId IdType="pubmed">14666245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Lu CW, Wang SJ. Luteolin protects the hippocampus against neuron impairments induced by kainic acid in rats. NeuroToxicol. 2016;55:48&#x2013;57. doi: 10.1016/j.neuro.2016.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2016.05.008</ArticleId><ArticleId IdType="pubmed">27185356</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezai-Zadeh K, Douglas SR, Bai Y, et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer&#x2019;s disease beta-amyloid production. J Cell Mol Med. 2009;13(3):574&#x2013;588. doi: 10.1111/j.1582-4934.2008.00344.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00344.x</ArticleId><ArticleId IdType="pmc">PMC2671567</ArticleId><ArticleId IdType="pubmed">18410522</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. Brain &#x201c;fog,&#x201d; inflammation and obesity: key aspects of 2 neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015;9:225. doi: 10.3389/fnins.2015.00225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00225</ArticleId><ArticleId IdType="pmc">PMC4490655</ArticleId><ArticleId IdType="pubmed">26190965</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao ZH, Yao XL, Zhang Y, Zhang SF, Hu JC. Luteolin could improve cognitive dysfunction by inhibiting neuroinflammation. Neurochem Res. 2018;43(4):806&#x2013;820. doi: 10.1007/s11064-018-2482-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-018-2482-2</ArticleId><ArticleId IdType="pubmed">29392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratton G, Weaver SR, Burley CV, et al. Dietary flavanols improve cerebral cortical oxygenation and cognition in healthy adults. Sci Rep. 2020;10(1):19409. doi: 10.1038/s41598-020-76160-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76160-9</ArticleId><ArticleId IdType="pmc">PMC7687895</ArticleId><ArticleId IdType="pubmed">33235219</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi SA, Chamoli A. Polyphenols as an effective therapeutic intervention against cognitive decline during normal and pathological brain aging. Adv Exp Med Biol. 2020;1260:159&#x2013;174. doi: 10.1007/978-3-030-42667-5_7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-42667-5_7</ArticleId><ArticleId IdType="pubmed">32304034</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjunath SH, Thimmulappa RK. (2021) Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: potential role in prevention and management of COVID-19. J Pharm Anal.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450231</ArticleId><ArticleId IdType="pubmed">34567823</ArticleId></ArticleIdList></Reference><Reference><Citation>Simsek Y, Baran SS, Aslim B. In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. J Mol Graph Model. 2021;109:108038. doi: 10.1016/j.jmgm.2021.108038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2021.108038</ArticleId><ArticleId IdType="pmc">PMC8479391</ArticleId><ArticleId IdType="pubmed">34607208</ArticleId></ArticleIdList></Reference><Reference><Citation>Di PF, Derosa G, Maffioli P, et al. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med. 2021;14:2359&#x2013;2366. doi: 10.2147/IJGM.S318720.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S318720</ArticleId><ArticleId IdType="pmc">PMC8197660</ArticleId><ArticleId IdType="pubmed">34135619</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC. Luteolin supplements: all that glitters is not gold. Biofactors. 2020;47(2):242&#x2013;244. doi: 10.1002/biof.1689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1689</ArticleId><ArticleId IdType="pubmed">33159817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartvig P, Larsson BS, Lindberg BS, et al. Influence of monoamine oxidase inhibitors and a dopamine uptake blocker on the distribution of 11C-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 11C-MPTP, in the head of the rhesus monkey. Acta Neurol Scand. 1986;74(1):10&#x2013;16. doi: 10.1111/j.1600-0404.1986.tb04618.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1986.tb04618.x</ArticleId><ArticleId IdType="pubmed">3490110</ArticleId></ArticleIdList></Reference><Reference><Citation>Serreli G, Deiana M. Extra virgin olive oil polyphenols: modulation of cellular pathways related to oxidant species and inflammation in aging. Cells. 2020;9(2):478. doi: 10.3390/cells9020478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020478</ArticleId><ArticleId IdType="pmc">PMC7072812</ArticleId><ArticleId IdType="pubmed">32093046</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592&#x2013;602. doi: 10.1016/j.clinthera.2013.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2013.04.006</ArticleId><ArticleId IdType="pubmed">23688534</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilioni I, Taliou A, Francis K, Theoharides TC. Children with autism spectrum disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6. Transl Psychiatry. 2015;5:e647. doi: 10.1038/tp.2015.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2015.142</ArticleId><ArticleId IdType="pmc">PMC5545641</ArticleId><ArticleId IdType="pubmed">26418275</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Gomes J. Neuropathogenesis of SARS-CoV-2 infection. Elife. 2020;9:e59136. doi: 10.7554/eLife.59136.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.59136</ArticleId><ArticleId IdType="pmc">PMC7392602</ArticleId><ArticleId IdType="pubmed">32729463</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhadian SF, Seilhean D, Spudich S. Neuropathogenesis of acute coronavirus disease 2019. Curr Opin Neurol. 2021;34(3):417&#x2013;422. doi: 10.1097/WCO.0000000000000944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000944</ArticleId><ArticleId IdType="pubmed">33852526</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73&#x2013;82. doi: 10.1038/s41577-020-00480-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00480-0</ArticleId><ArticleId IdType="pmc">PMC7747004</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Lauritano D, Ronconi G, Calvisi V, Conti P. Antibodies for COVID-19 - which, when and how long? J Biol Regul Homeost Agents. 2021;35(2):417&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">33896155</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobedo RA, Singh DK, Kaushal D. Understanding COVID-19: from dysregulated immunity to vaccination status quo. Front Immunol. 2021;12:765349. doi: 10.3389/fimmu.2021.765349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.765349</ArticleId><ArticleId IdType="pmc">PMC8632224</ArticleId><ArticleId IdType="pubmed">34858417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneussl MP, Richardson JB. Alpha-adrenergic receptors in human and canine tracheal and bronchial smooth muscle. J Appl Physiol Respir Environ Exerc Physiol. 1978;45(2):307&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">28308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata AF, Cheng CA, Desjardins M et al. (2021) Circulating SARS-CoV-2 vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>